Home / Stocks / Symbiotec Pharmalab Ltd
SYMBIOTEC

Symbiotec Pharmalab Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,604.8

Change

-16.5 (-1.02%)

Open

₹1,624.8

Prev. Close

₹1,621.3

Day High

₹1,644.1

Day Low

₹1,584.0

Volume Analysis

Traded

164,369

Delivered

56,569

Delivery %

34.42%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (27.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (59.8%)
  • •Strong 3-year revenue growth (15.3%)

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,698.04 ₹1,671.07 ₹1,637.94 ₹1,610.97 ₹1,577.84 ₹1,550.87 ₹1,517.74
Fibonacci ₹1,671.07 ₹1,648.11 ₹1,633.93 ₹1,610.97 ₹1,588.01 ₹1,573.83 ₹1,550.87
Camarilla ₹1,621.33 ₹1,615.82 ₹1,610.31 ₹1,610.97 ₹1,599.29 ₹1,593.78 ₹1,588.27

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-2.29%

1 Month

+32.8%

3 Months

—

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹289.0

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.17%

Net margin 12.66% × asset turnover 0.43x × equity multiplier 1.5x

Company Overview

Sector

Healthcare

Market Cap

₹10,354 Cr

P/E (TTM)

70.0

ROE

11.7%

Book Value

₹212.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Symbiotec Pharmalab Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Valuation (2/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (27.0%). Strong 3-year EPS growth (59.8%).

TopFund Score — Fundamentals Quality

60/100 — Average

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

52

Valuation

2

Cash Flow

50

Corporate Governance

33

Momentum

94

Institutional Ownership

54

Business Quality

72

Risk & Volatility

66

Liquidity

65

From Screener.in

  • +Company has reduced debt.
  • −Stock is trading at 7.61 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 12.9% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of the Earnings conference call for the Analysts and Investors for the Quarter and Half year ended

Symbiotec will attend Avendus Spark investor conference on 16 November 2026 in Mumbai.

The News Paper advertisement with respect to the unaudited Financial Results of the company for the quarter and half year ended September 30, 2026

Audio recording of analysts’ and investors’ conference call held on November 06, 2026, posted online.

Signed 10-year take-or-pay CDMO deal to manufacture fermentation-based alternative protein for a European innovator.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2025 Sep 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 203 196 245 218 280
Expenses + 145 145 183 173 188
Operating Profit 58 50 62 45 92
OPM % 29.0% 26.0% 25.0% 21.0% 33.0%
Other Income + 3 0 0 0 0
Interest 5 6 7 6 6
Depreciation 11 11 20 22 22
Profit before tax 45 33 35 18 64
Tax % 33.0% 43.0% 22.0% 20.0% 19.0%
Net Profit + 30 19 28 14 52
EPS in Rs 47 30 4 2 8
Raw PDF — — — — —
YoY Sales growth — — — 7 43

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Sales + 633 682 567 716 752 869
Expenses + 438 550 497 544 549 630
Operating Profit 195 131 70 172 203 239
OPM % 31.0% 19.0% 12.0% 24.0% 27.0% 27.0%
Other Income + 7 3 6 7 4 -6
Interest 7 3 8 8 17 26
Depreciation 22 26 29 39 43 53
Profit before tax 173 105 39 132 147 153
Tax % 28.0% 27.0% 38.0% 23.0% 34.0% 28.0%
Net Profit + 123 78 23 100 97 110
EPS in Rs 23 14 4 18 152 18
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth — 8 -17 26 5 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 510 588 611 704 804 1,137 1,348
Borrowings + 47 65 218 247 544 391 336
Other Liabilities + 200 152 151 326 220 240 347
Total Liabilities 768 815 990 1,289 1,580 1,781 2,044
Fixed Assets + 261 280 299 448 438 1,120 1,091
CWIP 28 40 182 208 568 64 138
Investments 5 5 5 4 1 4 4
Other Assets + 474 490 504 628 572 592 811
Total Assets 768 815 990 1,289 1,580 1,781 2,044
Equity Capital 11 11 11 11 11 13 13

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 174 18 69 188 47 175
Cash from Investing Activity + -96 -32 -220 -206 -307 -227
Cash from Financing Activity + -79 15 146 22 278 36
Net Cash Flow -1 1 -5 3 19 -16
Free Cash Flow 87 -55 -155 -22 -261 -50
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 112 36 124 129 40 99

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

  Sep 2026
Public 29.77%
Promoters 33.28%
FII 3.79%
DII 33.17%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Symbiotec Pharmalab Ltd (this stock) 10,354 70.0 7.6 11.7%
Yatharth Hosp & Tra C S L 10,222 53.6 5.44 10.2%
Blue Jet Healthcare Ltd 9,989 70.9 — 52.1%
Park Medi World Limited 11,039 43.1 5.12 16.8%
Jupiter Life Line Hosp L 9,507 50.0 5.84 13.1%
Akums Drugs And Pharma L 11,279 29.9 3.22 8.45%
Viyash Scientific Limited 11,285 46.6 3.56 7.39%

Which Mutual Funds Hold Symbiotec Pharmalab Ltd?

Frequently Asked Questions about Symbiotec Pharmalab Ltd

Community Sentiment

What are other investors saying about Symbiotec Pharmalab Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.